Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 7, 2026Cancer Research

Abstract B040: Understanding and Overcoming RAS-pathway Mediated Therapeutic Resistance and Disease Progression in Myeloproliferative Neoplasms

View Full Paper
Ask AI
Bookmark
Share

Authors

SCSubyeta ChowdhuryASAmritha Varshini Hanasoge SomasundaraCHCelina Huang

Discussion

Loading...

Member takes

Overview

This research uncovers strategies to combat resistance in myeloproliferative neoplasms, suggesting potential combinations to improve treatment outcomes.

Key Points

  • This research investigates RAS-mediated resistance to JAK2 inhibitors in myeloproliferative neoplasms and explores potential combination therapies.
  • Treatment of JAK2-mutant cell lines with exogenous RAS mutations and ruxolitinib.
  • Combination therapy tests of RAS inhibition, CDK4/6 inhibition, and JAK inhibition.
  • Use of Jak2 mutant mice models to observe differences in therapy response.
  • Assessment of cell viability, senescence, apoptosis, and cell cycle distribution.
  • Ruxolitinib leads to a selective expansion of cells with activating RAS mutations.
  • Combination therapy with RMC-7977 and abemaciclib showed potential to overcome resistance.
  • Clonogenic potential of RAS-mutated cells was observed to decrease with CDK4/6 inhibitors.
  • Co-culture experiments demonstrated enhanced competitiveness of Jak2Nras mutant cells, impacted by CDK4/6 inhibition.

Cite This Study

Chowdhury et al. (2026) studied this question.

synapsesocial.com/papers/69abc1c65af8044f7a4eab5ahttps://doi.org/10.1158/1538-7445.rasoncother26-b040
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Direct small molecule inhibition of RAS enhances JAK2 inhibitor therapy in preclinical models of myeloproliferative neoplasms2025
  2. 2Abstract 7225: Combination JAK1/2 and CDK8/19 inhibition demonstrates enhanced efficacy in myeloproliferative neoplasms2024
  3. 3Abstract 564: Therapeutic targeting of JAK/STAT signaling and histone acetyltransferase activity in post-myeloproliferative neoplasm secondary AML2024
  4. 4Abstract 3628: Combined mek and jak inhibition in vitro is an effective strategy in overcoming jak inhibitor resistance in primary myelofibrosis (PMF)2024 · 1 citations
  5. 5Abstract B096: Mutant and Wildtype RAS Crosstalk and Stoichiometric Deficiencies Determine Sensitivity to RAS Pathway Targeted Therapies2025